PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
Clinical trials for PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow lung damage in scarring disease
Disease control OngoingThis phase 2 trial tests an experimental drug called ENV-101 (taladegib) in 213 adults with idiopathic pulmonary fibrosis, a disease that causes lung scarring and makes breathing harder. Participants take either the drug or a placebo daily for several months. The main goal is to …
Matched conditions: PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Breathing in xenon gas could reveal hidden lung damage
Knowledge-focused OngoingThis study explores whether a special MRI scan using xenon gas can spot early signs of lung scarring and heart strain in people with progressive lung fibrosis. About 30 adults already on anti-fibrotic medication will be scanned and followed over time. The goal is to see if this i…
Matched conditions: PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC